IDEAYA's IDE849 Shows Strong Promise for Lung Cancer Patients

IDE849, a new DLL3-targeting drug for SCLC, shows strong efficacy with high response rates (up to 77.1%) and activity in brain metastases. It has a manageable safety profile, offering new hope for patients.